These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 37328895)

  • 21. Bone health in pediatric transfusion-dependent beta-thalassemia: Circulating osteoprotegerin and RANKL system.
    Youssry I; Saad N; Madboly M; Samy RM; Hamed ST; Tawfik H; Elbatrawy SR; Kaddah N; Abd Elaziz D
    Pediatr Blood Cancer; 2022 Jan; 69(1):e29377. PubMed ID: 34699125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS).
    Kim HR; Lee SH; Kim HY
    Rheumatology (Oxford); 2006 Oct; 45(10):1197-200. PubMed ID: 16567356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Iron chelation therapy in Upper Egyptian transfusion-dependent pediatric homozygous beta-thalassemia major: impact on serum L-carnitine/free fatty acids, osteoprotegerin/the soluble receptor activator of nuclear factor-kappabeta ligand systems, and bone mineral density.
    Hamed EA; Mohamed NA; El-Metwally TH; Kamal MM
    J Pediatr Hematol Oncol; 2010 May; 32(4):267-73. PubMed ID: 20445416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum levels of osteoprotegerin and receptor activator of nuclear factor -κB ligand in children with early juvenile idiopathic arthritis: a 2-year prospective controlled study.
    Lien G; Ueland T; Godang K; Selvaag AM; Førre OT; Flatø B
    Pediatr Rheumatol Online J; 2010 Dec; 8():30. PubMed ID: 21134287
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure.
    Shaarawy M; Fathy SA; Mehany NL; Hindy OW
    Clin Chem Lab Med; 2007; 45(11):1498-503. PubMed ID: 17970704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between low bone mass and the serum RANKL and OPG in patients with nephrolithiasis.
    Mansour A; Aboeerad M; Qorbani M; Hashemi Taheri AP; Pajouhi M; Keshtkar AA; Larijani B; Mohajeri-Tehrani MR; Ganji MR
    BMC Nephrol; 2018 Jul; 19(1):172. PubMed ID: 29996796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of Serum sRANKL, sRANKL/OPG Ratio, and Other Bone Turnover Markers with the Estimated 10-Year Risk of Major and Hip Osteoporotic Fractures in Rheumatoid Arthritis: A Cross-Sectional Study.
    Nava-Valdivia CA; Ponce-Guarneros JM; Saldaña-Cruz AM; Corona-Sanchez EG; Ramirez-Villafaña M; Perez-Guerrero EE; Murillo-Saich JD; Contreras-Haro B; Vazquez-Villegas ML; Gonzalez-Ponce F; Bonilla-Lara D; Jacobo-Cuevas H; Centeno-Valadez JD; Echeverria-Gonzalez G; Cerpa-Cruz S; Alcaraz-Lopez MF; Cardona-Muñoz EG; Salazar-Paramo M; Gonzalez-Lopez L; Gamez-Nava JI
    Biomed Res Int; 2021; 2021():5567666. PubMed ID: 34497849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disturbance of the OPG/RANK/RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis.
    Bai P; Sun Y; Jin J; Hou J; Li R; Zhang Q; Wang Y
    Respir Res; 2011 Dec; 12(1):157. PubMed ID: 22176920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of OPG and RANKL gene polymorphisms with bone mineral density in Indian women.
    Nair S; Bhadricha H; Patil A; Surve S; Joshi B; Balasinor N; Desai M
    Gene; 2022 Oct; 840():146746. PubMed ID: 35868414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The balance between soluble receptors regulating IL-6 trans-signaling is predictive for the RANKL/osteoprotegerin ratio in postmenopausal women with rheumatoid arthritis.
    Oelzner P; Franke S; Lehmann G; Eidner T; Hein G; Wolf G
    Rheumatol Int; 2012 Jan; 32(1):199-206. PubMed ID: 20821212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major.
    Pietrapertosa AC; Minenna G; Colella SM; Santeramo TM; Renni R; D'Amore M
    Panminerva Med; 2009 Mar; 51(1):17-23. PubMed ID: 19352306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Receptor Activator of Nuclear Factor κ-Β Ligand/Osteoprotegerin Axis in Adults with Hb S/β-Thalassemia and β-Thalassemia Trait.
    Tombak A; Boztepe B; Akbayir S; Dogru G; Sungur MA
    Hemoglobin; 2020 Sep; 44(5):334-337. PubMed ID: 32873083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Osteoprotegerin Polymorphisms in a Mexican Population with Rheumatoid Arthritis and Generalized Osteoporosis: A Preliminary Report.
    Zavala-Cerna MG; Moran-Moguel MC; Cornejo-Toledo JA; Gonzalez-Montoya NG; Sanchez-Corona J; Salazar-Paramo M; Nava-Zavala AH; Aguilar-Chavez EA; Alcaraz-Lopez MF; Gonzalez-Sanchez AG; Gonzalez-Lopez L; Gamez-Nava JI
    J Immunol Res; 2015; 2015():376197. PubMed ID: 26065000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis.
    Brabnikova-Maresova K; Jarosova K; Pavelka K; Stepan JJ
    Arthritis Res Ther; 2014 Oct; 16(5):460. PubMed ID: 25280749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of RANKL and OPG on bone mineral density in pre-dialysis chronic renal failure.
    Fahrleitner-Pammer A; Dobnig H; Dimai HP; Holzer H; Benesch T; Borchhardt K; Cejka D; Haas M
    Clin Nephrol; 2009 Jun; 71(6):652-9. PubMed ID: 19473634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study.
    Stern A; Laughlin GA; Bergstrom J; Barrett-Connor E
    Eur J Endocrinol; 2007 May; 156(5):555-62. PubMed ID: 17468191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The RANKL/OPG system and bone mineral density in patients with chronic liver disease.
    Moschen AR; Kaser A; Stadlmann S; Millonig G; Kaser S; Mühllechner P; Habior A; Graziadei I; Vogel W; Tilg H
    J Hepatol; 2005 Dec; 43(6):973-83. PubMed ID: 16143421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone loss in relation to serum levels of osteoprotegerin and nuclear factor-kappaB ligand: the Tromsø Study.
    Jørgensen L; Vik A; Emaus N; Brox J; Hansen JB; Mathiesen E; Vestergaard P
    Osteoporos Int; 2010 Jun; 21(6):931-8. PubMed ID: 19701599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The influence of Lys3Asn polymorphism in the osteoprotegerin gene on bone mineral density in Chinese postmenopausal women.
    Zhao HY; Liu JM; Ning G; Zhao YJ; Zhang LZ; Sun LH; Xu MY; Uitterlinden AG; Chen JL
    Osteoporos Int; 2005 Dec; 16(12):1519-24. PubMed ID: 15782282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synovial fluid RANKL and matrix metalloproteinase levels in enthesitis related arthritis subtype of juvenile idiopathic arthritis.
    Agarwal S; Misra R; Aggarwal A
    Rheumatol Int; 2009 Jun; 29(8):907-11. PubMed ID: 19052752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.